METHODS, THERAPIES AND USES FOR TREATING CANCER
The present disclosure describes single agent and combination therapies and uses for the treatment of cancer and/or cancer-associated diseases. The single agent and combinations therapies include a BCMA antibody.
1 .- 51 . (canceled)
52 . A method of treating cancer, comprising administering to the subject a combination therapy which comprises a first therapeutic agent and a second therapeutic agent, wherein the first therapeutic agent is a BCMA bispecific antibody and the second therapeutic agent is an anti-PD-1 antibody or an anti-PD-L1 antibody.
53 . The method of claim 52 , wherein the BCMA bispecific antibody is PF-06863135, and the second therapeutic agent is an anti-PD-1 antibody.
54 . The method of claim 53 , wherein the anti-PD-1 antibody is sasanlimab.
55 . The method of claim 52 , wherein the BCMA bispecific antibody is PF-06863135, the second therapeutic agent is an anti-PD-1 antibody sasanlimab and the cancer is multiple myeloma.
56 . A method of treating cancer, comprising administering to the subject a combination therapy which comprises a first therapeutic agent and a second therapeutic agent, wherein the first therapeutic agent is BCMA bispecific antibody and the second therapeutic agent is a gamma secretase inhibitor.
57 . The method of claim 56 , wherein the BCMA bispecific antibody is PF-06863135.
58 . The method of claim 56 , wherein the BCMA bispecific antibody is PF-06863135, and the gamma secretase inhibitor is nirogacestat, or a pharmaceutically acceptable salt thereof.
59 . The method of claim 56 , wherein the BCMA bispecific antibody is PF-06863135, the gamma secretase inhibitor is nirogacestat, or a pharmaceutically acceptable salt thereof, and the cancer is multiple myeloma.